



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

6

Complete if Known

Application Number	10/777,792
Filing Date	February 11, 2004
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Kimberly A. Ballard
Attorney Docket Number	15270J-004766US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	855	7,195,761	03-27-2007	Holtzman et al.	
	878	7,189,819	03-13-2007	Basi et al.	
	879	7,179,892	02-20-2007	Basi et al.	
	880	7,014,855	03-21-2006	Schenk	
	881	6,982,084	01-03-2006	Schenk	
	866	6,962,984	11-08-2005	Ishiwata et al.	
	892	6,923,964	08-02-2005	Schenk	
	884	2005/0152878 A1	07-14-2005	Solomon et al.	
	882	6,787,139	09-07-2004	Schenk	
	849	6,727,349	04-27-2004	LaRosa et al.	
	870	2003/0207828 A1	11-06-2003	Ishiwata et al.	
	869	2003/0135035 A1	07-17-2003	Shannon	
	883	6,582,945	06-24-2003	Raso	
	871	2003/0092145 A1	05-15-2003	Jira et al.	
	867	5,866,129	02-02-1999	Chang et al.	
	860	5,858,981	01-12-1999	Schreiber et al.	
	885	5,798,102	08-25-1998	McMichael et al.	
	876	5,731,284	03-24-1998	Williams	
	868	5,245,015	09-14-1993	Fung et al.	
U.S. PATENT APPLICATIONS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	899	11/358,951	02-22-2006	Solomon et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	853	EP	921 189	B1	01-12-2005			<input type="checkbox"/>
	842	EP	1 481 992	A2, A3	12-01-2004			<input type="checkbox"/>
	848	WO	05/026211	A2, A3	03-24-2005			<input type="checkbox"/>
	847	WO	04/071408	A2	08-26-2004			<input type="checkbox"/>
Examiner Signature					Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/777,792
				Filing Date	February 11, 2004
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
Sheet	2	of	6	Attorney Docket Number	15270J-004766US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ²	Number ⁴	Kind Code ⁵ (if known)				
	846	WO	04/044204	A2, A3	05-27-2004			<input type="checkbox"/>
	845	WO	03/072036	A2, A3	09-04-2003			<input type="checkbox"/>
	854	WO	95/07301	A1	03-16-1995			<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/777,792
				Filing Date	February 11, 2004
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
Sheet	3	of	6	Attorney Docket Number	15270J-004766US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	875	ARD et al., "Scavenging of Alzheimer's Amyloid β -Protein by Microglia in Culture," <u>J. Neuroscience Research</u> , 43:190-202 (1996).	<input type="checkbox"/>
	898	ASKELOF et al., "Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of <i>Bordetella pertussis</i> toxin subunit S1," <u>PNAS</u> , 87:1347-1351 (1990).	<input type="checkbox"/>
	858	BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A β antibody," <u>J. Clin. Invest.</u> , 116(3):825-832 (2006).	<input type="checkbox"/>
	891	CASADESUS et al., "The Estrogen Myth: Potential Use of Gonadotropin-Releasing Hormone Agonists for the Treatment of Alzheimer's Disease," <u>Drugs R D</u> , 7(3):187-193 (2006).	<input type="checkbox"/>
	901	CASEY, S.O., "Posterior Reversible Encephalopathy Syndrome: Utility of Fluid-attenuated Inversion Recovery MR Imaging in the Detection of Cortical and Subcortical Lesions," <u>Amer J Neuroradiol</u> , 21:1199-1206 (2000).	<input type="checkbox"/>
	859	COMERY et al., "Passive Immunization Against β -Amyloid Leads to Acute Cognition Improvement," <u>Society for Neuroscience</u> , abstract, Washington DC, 11/12-16/05.	<input type="checkbox"/>
	861	DE FELICE et al., " β -Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease," <u>Cell Mol. Neurobiol.</u> , 22(5/6):545-563 (2002).	<input type="checkbox"/>
	893	DE LA CRUZ et al., "Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," <u>J Biol Chem</u> , 263(9):4318-4322 (1988).	<input type="checkbox"/>
	862	DISIS et al., "Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines," <u>Blood</u> , 88(1):202-210 (1996).	<input type="checkbox"/>
	852	European Search Report of 1/16/07 for European Application 04776252.1-2405.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/777,792
				Filing Date	February 11, 2004
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
Sheet	4	of	6	Attorney Docket Number	15270J-004766US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	873	GEYLIS et al., "Immunotherapy of Alzheimer's disease 9AD): From murine models to anti-amyloid beta 9Ab) human monoclonal antibodies," <u>Autoimmunity Rev.</u> , 5:33-39 (2000).	<input type="checkbox"/>
	902	GILMAN, S. et al., "Clinical Effects of Abeta Immunization (AN1792) in Patients with AD in an Interrupted Trial," <u>Neurology</u> , 64:1553-1562 (2005).	<input type="checkbox"/>
	896	GROSS et al., "Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius," <u>Am J Physiol Regul Integr Comp Physiol</u> , 259:R1131-R1138 (1990).	<input type="checkbox"/>
	887	IDUSOGIE et al., "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunology</u> , 164:4178-4184 (2000).	<input type="checkbox"/>
	895	KHATOON et al., "Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer's disease and control brains," <u>FEBS Letters</u> , 351:80-84 (1994).	<input type="checkbox"/>
	863	KIMCHI et al., "Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy," <u>J. Neuropath Exp. Neurol.</u> , 60(3):274-279 (2001).	<input type="checkbox"/>
	843	KLYUBIN et al., "Anti-A β Antibodies Prevent Block of Long-Term Potentiation In the CA1 Area of Rat Hippocampus <i>In Vivo</i> by naturally Produced A β Oligomers," <u>Neurobiology of Aging</u> , 25:S224-S225, abstract P2-004, pages S224-S225 (2004).	<input type="checkbox"/>
	888	KUBY, J., eds., pages 108-109, 131-132 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	<input type="checkbox"/>
	889	LIU et al., "Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis," <u>Proc. Natl. Acad. Sci.</u> , 95:13266-13271 (1998).	<input type="checkbox"/>
	886	MORGAN et al., "The N-terminal end of the C _H 2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc γ RII and Fc γ RIII binding," <u>Immunology</u> , 86:319-324 (1995).	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/777,792
				Filing Date	February 11, 2004
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
Sheet	5	of	6	Attorney Docket Number	15270J-004766US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	850	PCT Search Report of 8/8/06 for application PCT/US2005/045515.	<input type="checkbox"/>
	872	PCT Search Report of 4/6/06 and Written Opinion of 4/8/06 for application PCT/US04/44093.	<input type="checkbox"/>
	903	PCT Search Report of 10/01/2007 and Written Opinion of 10/01/2007 for application PCT/US07/09499.	<input type="checkbox"/>
	890	PEREZ et al., "The β -Amyloid Precursor Protein of Alzheimer's Disease Enhances Neuron Viability and Modulates Neuronal Polarity," <u>J. Neurosci.</u> , 17(24):9407-9414 (1997).	<input type="checkbox"/>
	864	PIERA et al., "Cytokines as adjuvants: effects on the immunogenicity of NeuAc alpha 2-GalNAc alpha-O-Ser/Thr (sialyl-Tn)," <u>Int. J. Cancer</u> , 55(1):148-152 (1993).	<input type="checkbox"/>
	877	PLUCKTHUN, A., "Mono- and Bivalent Antibody Fragments Produced in <i>Escherichia coli</i> : Engineering, Folding and Antigen Binding," <u>Immunological Reviews</u> , 130:151-188 (1992).	<input type="checkbox"/>
	865	ROSES, A.D., "Apolipoprotein E alleles as risk factors in Alzheimer's disease," <u>Annu. Rev. Med.</u> , 47:387-400 (1996).	<input type="checkbox"/>
	851	SALDANHA et al., "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <u>Molecular Immunology</u> , 36:709-719 (1999).	<input type="checkbox"/>
	856	SEUBERT et al., "Antibody Capture of Soluble A β does not Reduce Cortical A β Amyloidosis in the PDAPP Mouse," <u>Neurodegenerative Diseases</u> , (2007).	<input type="checkbox"/>
	874	SOTO et al., "The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis," <u>Biochem. J.</u> , 314:701-707 (1996).	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/777,792
				Filing Date	February 11, 2004
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
Sheet	6	of	6	Attorney Docket Number	15270J-004766US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	857	TRAVIS, J., "Saving the Mind Faces High Hurdles," <u>Science</u> , 309:731-734 (2005).	<input type="checkbox"/>	
	844	UniProtKB/Swiss-Prot entry P18525, pages 1-3 downloaded from http://www.expasy.org/cgi-bin/niceprot.pl/printable?ac=P18525 on 2/8/97, "HV54_Mouse" (11/1/90).	<input type="checkbox"/>	
	897	WHITCOMB et al., "Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain," <u>Am J Physiol Gastrointest Liver Physiol</u> , 259:G687-G691 (1990).	<input type="checkbox"/>	
	894	WU et al., "Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of <i>Salmonella</i> ," <u>PNAS</u> , 86:4726-4730 (1989).	<input type="checkbox"/>	
	900	Wyeth, Annual Review 2005: Creating Value...Advancing Health (February 27, 2006).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.